← All compounds
peptide0 listings
Vilon
Vilon (KE)
Immune/thymic dipeptide bioregulator.
Immune researchLongevity research
/ research index
The research base
Research Maturity
★★☆☆☆
2/5 — Volume of studies
Evidence Strength
★★☆☆☆
2/5 — Quality of evidence
Khavinson-series short-peptide bioregulator studied for tissue-specific gene regulation.
/ mechanism of action
How it works
Short peptide proposed to bind DNA and modulate tissue-specific gene expression (peptide bioregulator hypothesis).
/ research dosing
Common research protocols
Range
~10mcg-10mg depending on form (research-stage)
Frequency
Daily during cycle
Route
Subcutaneous or oral (research-dependent)
Cycle
10-20 day cycles, often 2x/year
Research notes
Part of the Khavinson short-peptide bioregulator series. Evidence base is primarily from Russian research groups; treat maturity as early.
References
FOR RESEARCH USE ONLY. Doses listed are compiled from published research literature, FDA-approved drug labels, and well-documented research community practice. Not medical advice.
/ standalone use
As a solo compound
Standalone bioregulator research; typically short cycles 2x/year.
/ side effects
What to know
Generally well-tolerated in available studies; limited modern trial data.
/ timeline
Realistic expectations
10-20 day cycles
FOR RESEARCH USE ONLY. Vilon is intended for laboratory research and not for human consumption.